JAN 3 0 2004

Typed or printed

Signature

Patricia S. Rocha-Tramaloni

J.	JAN J	2004	no nomen		nt and T	rademark	PTO/SB/21 (01-03) d for use through 04/30/2003. OMB 0651-0031 c Office; U.S. DEPARTMENT OF COMMERCE			
<del></del>	Idapula Par	PER WORK REGION ACT OF 1995	. no berson:	Application Number		omauon 07,543	unless it displays a valid OMB control number.			
TRANSMITTAL				Filing Date			October 30, 2003			
		FORM	A 411.14			Cai et al.				
(to t	be used for	all correspondence after initial								
				Examiner Name						
Total	Number of	Pages in This Submission		Attorney Docket Number	2145	4 US				
			ENCI	LOSURES (Check all tha	t apply	)				
	Amendment Af Af Extension Express A Information Certified Cocument Response Incomplet	iter Final ifidavits/declaration(s) i of Time Request Abandonment Request in Disclosure Statement Copy of Priority	Remar	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a  Provisional Application  Power of Attorney, Revocation  Change of Correspondence Addu  Ferminal Disclaimer  Request for Refund  CD, Number of CD(s)  Les A1-A3, B1-B11 and C1-C4.	ress		After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):			
		SIGNA	TURE C	F APPLICANT, ATTORN	EY, C	R AG	ENT			
Firm Patricia S. Rocha-Tramale or Individual		oni								
Signate		U								
Date		January 28, 2004								
		С	ERTIFIC	CATE OF TRANSMISSION	I/MAI	LING				
I hereby mail in a	certify that to n envelope	this correspondence is being tr addressed to: Commissioner f	ansmitted to or Patents, I	o the USPTO or deposited with the U P.O. Box 1450, Alexandria, VA 223	nited Sta 13 on th	ates Post is date Ja	al Service with sufficient postage as first class anuary 28 2004			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date January 28, 2004

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## PATENT APPLICATION



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors:

Cai, et al.

Serial No. 10/697,543, filed October 30, 2003

(Ref. No. 21454 US)

For: AMINO-SUBSTITUTED DIHYDROPYRIMIDO[4,5-D]PYRIMIDINONE

**DERIVATIVES** 

## INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 January 28, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A3, B1-B11, and C1-C4 listed on Form PTO-1449 are enclosed. Document A4 is not being submitted because it is a US patent.

Document B4, which is not written in the English language, corresponds to Document A1. Documents B6 and B7, which are not written in the English language correspond to Documents A2 and A3, respectively.

Serial No. 10/697,543

Filed: October 30, 2003

Enclosed is a Search Report, dated April 4, 2003, which was issued by the

European Patent Office in the European application corresponding to the captioned

application. The Search Report lists Documents A4, and B1-B8.

The Examiner's attention is also directed to co-pending application US Serial No.

10/689,235 (CD 21269 US1) filed in the US on October 20, 2003, a copy of which is

enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the

first Office Action on the merits or within three months of the filing date for the above

application, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Patricia S. Rocha-Tramaloni

(Reg. No. 31,054)

340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-2441

Telefax: (973) 235-2363

Attachments

138446

2

( )	Substitute for form 1449A/PTO					Comp	lete if Kn	own					
	/n   ·- · · · · · · · · · · · · · · · ·					Application Number	,543						
- 701 - 7 5	STATEMENT BY APPLICANT					Filing Date	er 30, 2003						
Sheet	(Use several sheets if necessary)				1	First Name Inventor	al.						
Sheet	1	of 1	i necessary	)		Attorney Docket Number	21454	US					
				U.S. I		NT DOCUMENTS							
	Examiner Cite Initials' No. V. S. Patent Document Kind Code												
Examiner Initials'			Kind Cod			Name of Patentee or Ap Cited Documen		Date of Publication of Cited document					
Illitiais	No.	Number (if known)		own)	Cited Documen	MM-DD-YYYY							
	<b>A1</b> 4,503,049				Biere, et al.	03/5/1985							
	A2	4,473,560				Biere, et al.	09/25/1984						
	A3	4,784,9	993			Bosies		11/15/1988					
	A4	5,866,	556			Heikkila-Hoikka		02/02/1999					
	FOREIGN PATENT DOCUMENTS												
Examiner	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of	T <sup>e</sup>						
Initials'	No.	Office Number Kind		Kind	Applicant of Cited Docum		ent	Cited Document					
				(if known)				MM-DD-YYYY					
_			Wa	rner Lambert Co.	12/02/1999								
			Ari	ad Pharmaceuticals I	06/21/2001								
	<b>B3</b>	EP 0 186 405			The	e Procter & Gamble (	07/02/1986						
	<b>B4</b> EP 0 084 822			Sch	nering Aktiengesellsc	08/03/1983							
	<b>B5</b>	EP 0 304 962 EP 0 085 321 EP 0 170 228			The	Procter & Gamble (	03/01/1989						
	<b>B6</b>				Sch	nering Aktiengesellsc	08/10/1983						
	<b>B</b> 7				Boo	ehringer Mannheim (	02/05/1986						
	<b>B8</b> WO 94/09017			The	Upjohn Co.	04/28/1994							
	B9	WO 00/24744 WO 01/29041			F.F	Ioffmann-La Roche A	05/04/2000						
	B10				F.F	Ioffmann-La Roche A	04/26/2001						
	B11	WO 01	/29042		F.F	Ioffmann-La Roche A	\G	04/26/2001					

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	<b>C</b> 1	Kinko, K. et al., Can. J. Chem. Vol. 51 (1973) pgs. 333-337	
	C2	Merrifield, B. et al., Fed. Proc. Fed. Amer. Soc. Exp. Biol. Vol. 21 (1962) p. 412	
	<b>C3</b>	Okuda, T. et al., J. Org. Chem. Vol. 24 (1959) pgs. 14-16	
	C4	Ansel, H. et al., Pharm. Dosage Forms & Drug Delivery Systems (6 <sup>th</sup> Ed.) 1995 p. 196	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Benter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Xind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation or abstract is attached.